Navigation Links
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
Date:8/6/2009

Excluding non-cash compensation expense related to stock options, operating expenses for Regulus were $2.7 million and $5.5 million for the three and six months ended June 30, 2009 compared to $1.7 million and $2.8 million for the same periods in 2008. The increase is primarily related to Regulus' continued efforts to build its team to support its internal microRNA programs and its GSK collaboration. Regulus generated a loss from operations, excluding non-cash compensation expense related to stock options, of $1.6 million and $3.8 million for the three and six months ended June 30, 2009 compared to $1.1 million and $2.1 million for the same periods in 2008.

Business Highlights

"During the last quarter, we and Genzyme made great progress regarding mipomersen on two important fronts, advancing the clinical development program and refining our regulatory strategy. We reported positive top-line results from a Phase 3 study of mipomersen in the largest, placebo-controlled Phase 3 study in homozygous FH patients. We reported that the study met its primary endpoint with a 25% reduction in LDL-C after 26 weeks of treatment with mipomersen versus 3% for placebo and all of its secondary endpoints in a highly statistically significant manner. We are very pleased with the performance of mipomersen in this study. These data are a significant milestone in the clinical development of mipomersen and support our efforts to make the drug available to patients in need," said Ms. Parshall.

"In addition to reporting data from the first of our Phase 3 trials for mipomersen, we and Genzyme refined and communicated the regulatory path for mipomersen in the United States and Europe. While the strategy continues to evolve, Genzyme plans to file the first NDA for mipomersen in the U.S. for homozygous FH in the second half of 2010, with a similar filing in Europe shortly afterwards. Data from our Phase 3 study in
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... 6 Physicians Interactive (PI), a leading ... today announced a partnership with OPTIMIZERx Corp ... healthcare professionals with SampleMD, a solution that  allows for ... vouchers, prescription co-pay coupons and other support information directly ...
... 6 e-MDs, an industry leader in the ... and practice management (PM) solutions,  congratulates  the Diabetes ... Medicine of Fort Collins, CO, for their recognition ... Excellence recipients.  The Healthcare Information and Management Systems ...
Cached Medicine Technology:Physicians Interactive Launches Partnership with SampleMD to Expand Sampling Options for Clinicians and Reduce Costs for Patients 2Physicians Interactive Launches Partnership with SampleMD to Expand Sampling Options for Clinicians and Reduce Costs for Patients 3e-MDs Clients Win HIMSS Davies Awards of Excellence 2e-MDs Clients Win HIMSS Davies Awards of Excellence 3e-MDs Clients Win HIMSS Davies Awards of Excellence 4
(Date:4/23/2014)... was safe and effective in treating patients with ... , according to a new pilot study published ... online. Known as fecal microbiota transplantation, the treatment ... or a nasogastric tube. The findings suggest approaches ... available to patients. , A growing concern, ...
(Date:4/23/2014)... scientific director at the National Institute of Arthritis and ... 2014 recipient of the Ross Prize in Molecular Medicine, ... Molecular Medicine . The award will be given on ... in Manhattan, followed by scientific presentations by Dr. O,Shea ... National Institutes of Health. , The award, which includes ...
(Date:4/23/2014)... researchers have developed a way to detect and measure ... gold particles with tails of synthetic DNA., A team ... engineering, used gold nanoparticles to target and bind to ... splice variants, which can indicate the presence and stage ... variants in a cell can be determined by examining ...
(Date:4/23/2014)... falls below normal levels are more likely to have ... disease and type 2 diabetes. A new simple screening ... and possible treatment is described in an article in ... from Mary Ann Liebert, Inc., publishers. The article is ... website at http://www.liebertpub.com/jmh . , ...
(Date:4/23/2014)... evidence mounts showing the potential health benefits of probiotics, ... are taking supplements. And the chemical industry is getting ... health effects could deter growth, so the industry is ... according to the cover story in Chemical & ... the American Chemical Society. , Melody M. Bomgardner, a ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... Mothers, exposure during pregnancy to a class of air ... problems in their children. PAH are,released to air during ... coal, and other,organic material. , The study is the ... problems among school‐age children and two complementary measures of ...
... 21 (HealthDay News) -- Alzheimer,s disease and other types of ... brain, new research indicates. The findings from MRI brain ... to use MRI to predict the progression of dementias and ... San Francisco (UCSF) researchers said. They found that Alzheimer,s ...
... HealthDay Reporter , WEDNESDAY, March 21 (HealthDay ... treatments, alternative therapies such as acupuncture, acupressure and dietary ... sinusitis, a new pilot study suggests. The authors ... explore the potential of combining Western medicine with Eastern ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... epidemic to the United States and the economic value of ... to a new report. The problem is that estimates ... out only 10 years, while it may take much longer ...
... HealthDay Reporter , WEDNESDAY, March 21 (HealthDay News) ... in people already taking statins such as Lipitor, making ... alternative, a preliminary new study suggests. Two single-dose ... a group with high cholesterol showed that the drug, ...
... led by A. K. Rajasekaran, PhD, Director of the Nemours ... protein involved in cell function and regulation is stopped by ... published online in the American Journal of Physiology - ... is well recognized as a cause of lung cancer and ...
Cached Medicine News:Health News:Prenatal exposure to combustion-related pollutants and anxiety, attention problems in young children 2Health News:Alternative Medicine May Help Ease Chronic Sinusitis 2Health News:Alternative Medicine May Help Ease Chronic Sinusitis 3Health News:U.S. Underestimates Long-Term Costs of Obesity, Experts Say 2Health News:U.S. Underestimates Long-Term Costs of Obesity, Experts Say 3Health News:Statin Alternative Looks Promising in Early Trials 2Health News:Statin Alternative Looks Promising in Early Trials 3Health News:Nemours researchers uncover new evidence of cancer-causing agent present in gaseous phase of cigarette smoke 2
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: